Related Experiment Video
Updated: Mar 6, 2026
07:23
Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
Published on: May 30, 2025
1.3K
Long non-coding RNA CASC2 in human cancer
Giuseppe Palmieri1, Panagiotis Paliogiannis2, Maria Cristina Sini1
1Unit of Cancer Genetics, Institute of Biomolecular Chemistry (ICB), National Research Council (CNR), Traversa La Crucca 3, 07100, Sassari, Italy.
Critical Reviews in Oncology/Hematology
|March 6, 2017
Summary
Long non-coding RNAs (lncRNAs) are crucial in cancer. This review details the role of Cancer Susceptibility 2 (CASC2) in cancer development, progression, and treatment strategies.
Area of Science:
- Genomics
- Molecular Biology
- Oncology
Background:
- Long non-coding RNAs (lncRNAs) constitute over 90% of the human genome's non-coding information.
- lncRNAs are key regulators of gene expression, imprinting, transcription, and post-translational processing.
- These molecules play diverse roles in the pathophysiology of various cancers.
Purpose of the Study:
- To review the current understanding of Cancer Susceptibility 2 (CASC2) in human cancer.
- To elucidate the mechanisms and interactions of CASC2 in oncogenesis and progression.
- To summarize CASC2's involvement in the clinical management of cancer.
Main Methods:
- Literature review of studies on CASC2 and cancer.
- Analysis of CASC2's role in tumor suppressor activities.
- Examination of CASC2's interactions and regulatory functions in neoplastic diseases.
Main Results:
- CASC2 was initially identified as a tumor suppressor in endometrial carcinoma.
- Subsequent research has expanded the understanding of CASC2's functions across multiple cancer types.
- CASC2 is implicated in the genesis, progression, and potential therapeutic strategies for cancer.
Conclusions:
- CASC2 is a significant lncRNA with a multifaceted role in cancer.
- Further research into CASC2 mechanisms can inform clinical applications.
- CASC2 represents a potential target for cancer therapy and management.
Related Concept Videos
02:39lncRNA - Long Non-coding RNAs
10.0K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
10.0K
02:39lncRNA - Long Non-coding RNAs
3.8K
3.8K
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
10.0K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
10.0K
03:18Non-LTR Retrotransposons
13.6K
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
13.6K
01:03Rous Sarcoma Virus (RSV) and Cancer
6.5K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
6.5K
01:32RNA Splicing
61.0K
Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...
61.0K